In a boost for its phase III Indonesian diabetic foot infection trial, Recce becomes eligible for up to $85 million ... Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback